Statements (23)
Predicate | Object |
---|---|
gptkbp:instanceOf |
gptkb:company
|
gptkbp:CEO |
gptkb:Brian_Goff
|
gptkbp:focus |
oncology
rare diseases |
gptkbp:foundedYear |
2007
|
gptkbp:founder |
gptkb:Craig_Thompson
gptkb:David_Schenkein gptkb:Tak_Mak gptkb:Lewis_Cantley |
gptkbp:fullName |
gptkb:Agios_Pharmaceuticals,_Inc.
|
gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts,_United_States
|
https://www.w3.org/2000/01/rdf-schema#label |
AGIO
|
gptkbp:industry |
gptkb:biotechnology
|
gptkbp:ISIN |
US00847X1046
|
gptkbp:marketCap |
~$1.7 billion (2023)
|
gptkbp:notableProduct |
PYRUKYND (mitapivat)
TIBSOVO (ivosidenib) |
gptkbp:numberOfEmployees |
~350 (2023)
|
gptkbp:stockExchange |
gptkb:NASDAQ
|
gptkbp:stockSymbol |
gptkb:AGIO
|
gptkbp:website |
https://www.agios.com/
|
gptkbp:bfsParent |
gptkb:Agios_Pharmaceuticals
|
gptkbp:bfsLayer |
5
|